Spread The Word

News Releases

Date Title and Summary Additional Formats
Toggle Summary Clementia Announces Pricing of Initial Public Offering
MONTREAL , Aug. 2, 2017 /PRNewswire/ --  Clementia Pharmaceuticals Inc. (NASDAQ: CMTA) (the "Company" or "Clementia"), a clinical stage biopharmaceutical company, today announced the pricing of its initial public offering of 8,000,000 common shares at an initial public offering price of $15 .00 per
View HTML
Toggle Summary Phase 2 Part A Open Label Extension Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva Continues Positive Trends
MONTREAL, CANADA, March 28, 2017  – Clementia Pharmaceuticals Inc. today announced the preliminary results of its Phase 2 Part A Open Label Extension (OLE) palovarotene trial in the treatment of fibrodysplasia ossificans progressiva (FOP). All 40 subjects who enrolled into the double-blind,
View HTML
Toggle Summary Clementia Clinical Program: Queensland University of Technology (QUT) Institute of Health and Biomedical Innovation (IHBI) Begins Enrolling Patients in Palovarotene 2B Extension Study
MONTREAL, CANADA, November, 18, 2016  – Clementia is pleased to announce that the Queensland University of Technology (QUT) Institute of Health and Biomedical Innovation (IHBI) is treating FOP patients in Part B of the Phase 2 Open-label Extension Trial (PVO-1A-202). Prof. Dr.
View HTML
Toggle Summary Clementia Clinical Program: Necker Begins Enrolling Patients in Palovarotene 2B Extension Study
MONTREAL, CANADA, November, 18, 2016  – Clementia is pleased to announce that the Hôpital Necker of Paris is ready to enroll FOP patients into Part B of its Phase 2 Open-label Extension Trial, which is a new study in France called PVO-1A-204. Dr Geneviève Baujat is principal investigator at
View HTML
Toggle Summary Clementia Clinical Program: Clinical Trial Site for Palovarotene Study Opened in Argentina
MONTREAL, CANADA, November, 14, 2016  – Clementia is pleased to announce to the FOP community that Hospital Italiano in Buenos Aires is ready to enroll FOP patients into Part B of its Phase 2 Open-label Extension Trial (PVO-1A-202). Dra Carmen L De Cunto, MD, Pediatric Rheumatologist at the
View HTML
Toggle Summary Clementia Announces Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva
MONTREAL, CANADA, October, 14, 2016  – Clementia Pharmaceuticals Inc. today announced top-line results from its Phase 2 clinical trial investigating palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP). FOP is an extremely rare, serious disease in which an accumulation
View HTML
Toggle Summary Clementia Clinical Program: Opportunity for New Adult and Older Adolescent Subjects to Enroll in Palovarotene Study
MONTREAL, CANADA, August 8, 2016  – Clementia is pleased to announce to the FOP community that the implementation of Part B of its Phase 2 Open-label Extension Trial (PVO-1A-202) is progressing well and enrollment of adult or older adolescent subjects who have not previously participated in
View HTML
Toggle Summary Clementia Clinical Program: Next Step in Clementia’s Clinical Program for Fibrodysplasia Ossificans Progressiva (FOP)
MONTREAL, CANADA, June 13, 2016  – Clementia is pleased to announce that the Phase 2 Open-label Extension Trial (PVO-1A-202) has been modified to enroll up to 20 new participants and to investigate new palovarotene dosing regimens in participants with fibrodysplasia ossificans progressiva
View HTML
Toggle Summary Clementia Pharmaceuticals Joins Global FOP Community in Recognizing Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day
10 Year Anniversary of the Discovery of the Gene that Causes FOP MONTREAL, CANADA, April 23, 2016  – Clementia Pharmaceuticals Inc. today joins the FOP community in recognizing and supporting FOP Awareness Day 2016. FOP is a rare, severely disabling myopathy characterized by extra-skeletal
View HTML
Toggle Summary Positive Effects of Palovarotene on Spontaneous Heterotopic Ossification, Mobility, and Skeletal Growth in Mouse Models of FOP Reported in Journal of Bone and Mineral Research
MONTREAL, CANADA, April 14, 2016  – Clementia Pharmaceuticals Inc. today reports that the Journal of Bone and Mineral Research has published online a non-Clementia sponsored study describing palovarotene’s novel, beneficial effects on spontaneous heterotopic ossification, mobility, and
View HTML